Is adding CHM on top of conventional care (granulocyte colony‐stimulating factor (G‐CSF)/granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)/ interleukin‐3 (IL‐3)) more effective in improving leukopenia among adult patients receiving cancer palliative care? The gene discussed is CSF2; the disease is Decreased total leukocyte count.